Equity Overview
Price & Market Data
Price: $3.46
Daily Change: -$0.164 / 4.74%
Daily Range: $3.46 - $3.66
Market Cap: $1,050,665,984
Daily Volume: 3,151,015
Performance Metrics
1 Week: -2.23%
1 Month: -3.04%
3 Months: -26.42%
6 Months: 11.08%
1 Year: 20.62%
YTD: 19.80%
Company Details
Employees: 596
Sector: Health technology
Industry: Biotechnology
Country:
Details
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.